Fdanewsdrugdailybulletin

Nov. 20, 2019

Vol. 16 No. 225

View Archived Issues

Sign Up Now

Purdue Pharma Gets Six-Month Shield From Opioid Litigation

The judge previously gave the company one month to convince two dozen states that have not agreed to its proposed $10 billion settlement to go along with the injunction. Read More

Reblozyl Earns FDA’s First Approval for Rare Blood Disorder

Reblozyl was previously granted both fast track and orphan drug designations. Read More

Health Canada Approves Janssen’s Imbruvica for Chronic Lymphocytic Leukemia

The approval is the ninth indication for Imbruvica in Canada, and the first approval for a non-chemotherapy combination regimen for treatment-naïve patients with chronic lymphocytic leukemia. Read More

Strides Announces Relaunch of Prescription Ranitidine Tablets

Testing by the FDA showed that the tablets were within the acceptable limits for NDMA. Read More

U.S., EU and Japan Announce Progress on Antibacterial Research

The regulators are targeting antibacterial drugs for pediatric use. Read More